INVO_oneline.png

It has been an eventful year for Northwestern biotech startups who have achieved numerous milestones, including FDA clearances, clinical milestones, funds raised, and products launched. Below, you will find a summary of recent highlights, including opportunities to partner and invest.

 

A number of companies, denoted with "SF2022" will be in San Francisco from January 10-14 and are available for in-person meetings. Please contact us if you are interested in connecting with any of our companies, either in San Francisco or remotely.


If you would like to learn more about our new Ventures-in-Residence and Executives-in-Residence programs that will be housed at the new Northwestern incubator, please contact us.

 

We wish you a prosperous 2022!


The Innovation and New Ventures Team at Northwestern

NORTHWESTERN

INNOVATION AND STARTUP HIGHLIGHTS


THERAPEUTICS

Actuate logo.png

STARTUP: Actuate Therapeutics


Actuate is developing new therapeutic compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers. In addition, they are advancing their compounds for the treatment of inflammation leading to fibrosis and neurodegeneration.



INDICATIONS: ADVANCED CANCERS and INFLAMMATION

NEWS:

  • Phase 1/2 trial across multiple histologies is currently enrolling patients in leading US and EU institutions (1901 and 1902 Clinical Studies)
  • Received FDA Fast Track Designation for 9-ING-41 for treating patients with pancreatic cancer. Aug 2021 Press Release

_________* SF 2022 *_________

cavalon.png

STARTUP: Cavalon Therapeutics

FACULTY FOUNDER: D. James Surmeier


Cavalon is focused on mechanisms underlying Parkinson's disease and the targeting of a key neuronal calcium channel involved in the pathophysiology of neurodegenerative and neuropsychiatric disorders.



INDICATION: NEURODEGENERATIVE DISEASES

NEWS:

  • Published two manuscripts in 2021 supporting key clinical insights underlying its drug development strategy
  • Recently awarded grant funding from the Michael J. Fox Foundation for Parkinson’s Research
  • Established an intranasal device partnership to support the Nose-to-Brain delivery of its drug development program



\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \


**FUNDRAISING: Cavalon is currently raising additional foundation and government grant funding to support its preclinical-stage programs, and will be raising seed-stage financing in 2022.

Cour logo.jpg

STARTUP: COUR Pharmaceuticals

FACULTY FOUNDER: Stephen Miller


COUR Pharma is developing first-in-class therapies that reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR's lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease.


INDICATIONS: AUTOIMMUNE DISEASES, FOOD & ENVIIRONMENTAL ALLERGIES, AND RARE DISEASES

NEWS: 

  • FDA approval of IND application for clinical study of safety and efficacy of CNP-104 for Primary Biliary Cholangitis. (PBC) Oct 2021 Press Release
  • Ironwood Pharma signed an option to acquire exclusive license to develop and commercialize CNP-104, a Treatment of PBC. Nov 2021 Press Release

 

INDICATION: PEANUT ALLERGY

NEWS:

Design Pharma logo_new 300.png

STARTUP: Design Pharmaceuticals

FACULTY FOUNDER: Michael Jewett


Design Pharma enables enable rapid discovery and biosynthetic production of drug candidates at unprecedented scale. Their drug discovery engine unlocks the potential of nature-derived small molecule drug discovery by overcoming the many inherent challenges to data mining, access to molecular structures through biosynthesis and engineering inspired rapid design, build and test cycles for hit candidate identification and optimization of lead candidates. Their platform also offers unique opportunities for live biotherapeutics (LBP) and biologics discovery.



APPLICATION: DRUG DISCOVERY



\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \


**FUNDRAISING: Design is currently starting a series A fund raise.



**PARTNERING: Design is interested in continuing to expand its portfolio of pharma collaborations developing shared assets and advancing an internal pipeline of drug candidates for out-licensing. Our platform offers unique opportunities for live biotherapeutics and biologics discovery.

exicure logo.png

COMPANY: Exicure

FACULTY FOUNDER: Chad Mirkin


Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology.



INDICATIONS: GENETIC DISEASES & ONCOLOGY

NEWS:

  • Granted Orphan Drug Designation by FDA for Cavrotolimod (AST-008) for the treatment of patients with Merkel cell carcinoma (MCC) and in combination with anti-PD-1/PD-L1 antibodies for patients with advanced or metastatic MCC and cutaneous squamous cell carcinoma. March Press Release
  • Achieved response rate threshold to advance patient enrollment in the ongoing Phase 1b/2 Clinical trial of Cavrotolimod. More Details
Inomagen.png

STARTUP: Inomagen Therapeutics

FACULTY FOUNDER: Rishi Arora


Inomagen is developing gene therapy treatments for patients with chronic atrial fibrillation (AF). The company has identified fundamental molecular mechanisms in the creation of the AF disease state and major trans-genes to selectively target these mechanisms. In proof-of-concept studies, Inomagen’s gene therapy technology has demonstrated a marked decrease in AF in clinically relevant, large animal models (prevention and reversal).


INDICATION: ATRIAL FIBRILLATION

NEWS:


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Inomagen is closing a $500k round in the 1Q of 2022.

_________* SF 2022 *_________

Temprian Therapeutics.jpg

STARTUP: Temprian Therapeutics

FACULTY FOUNDER: I. Caroline Le Poole

 

Temprian is developing a new therapeutic for vitiligo using DNA coding a modified heat shock protein HSP70i to stop the autoimmune responses which can erroneously attack pigment cells.

 

INDICATION: VITILIGO

NEWS: Received $1M investment by 2Flo Ventures to execute pre-clinical studies with plans to file IND in 2022.

 

\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Temprian is pursuing a Series A round to support clinical trials.

Terra-Bioworks high-res logo.png

STARTUP: Terra Bioworks

FACULTY FOUNDER: Neil Kelleher


Terra Bioworks uses synthetic biology tools and technology to clone large microbial DNA pathways encoding rare and valuable small molecule therapeutic “drugs” and reprogram multiple type hosts, such as fungi, bacillus, and streptomyces, to manufacture new and existing natural product drugs. The company has previously cloned and expressed over 110 pathways from bacterial and fungal genomes and >300 pathways from metagenomic soil samples.


APPLICATION: DRUG DISCOVERY


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \

 

FUNDRAISING: Terra Bioworks is seeking a $10M Series A.

vanqua bio logo.jpg

STARTUP: Vanqua Bio

FACULTY FOUNDER: Dimitri Krainc


Vanqua's lead program is focused on developing small-molecule activators of glucocerebrosidase (GCase), an enzyme that regulates lipid homeostasis in cells, targeting neurodegeneration for Parkinson’s disease and Gaucher disease. In addition Vanqua Bio will also advance programs targeting the innate immune system, which, when overactivated, can accelerate the progression of several neurological diseases.



INDICATION: NEURODEGENERATIVE DISEASES

NEWS: Launched with Series B $85M Financing. Sept 2021 Press Release

Yobee logo v3.jpg

STARTUP: Yobee Care

FACULTY FOUNDER: Ruchi Gupta


Yobee has formulated a nature-based, triple-powered scalp, hair, & skin probiotic technology (Probyome™) that quickly and effectively reduces skin inflammation, redness, and itching, and clears the scalp of plaques and flakes.



INDICATION: DRY SCALP AND SKIN

NEWS:

  • Ongoing FDA IND Phase I & II clinical trial on the safety and efficacy for dry scalp conditions.
  • Overall Therapeutics Winner in Equalize 2021, a mentor program and pitch competition designed to decrease disparity of women academic inventors in entrepreneurship. Oct 2021 Pitch Video


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \


**FUNDRAISING: Yobee is currently raising a $1M seed round.

Calidi.png

Calidi Biotherapeutics, a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, exclusively licensed rights for Prof. Maciej Lesniak's stem cell based products loaded with adenovirus. His work, published in the June 29, 2021 Lancet Oncology, demonstrates safety and efficacy of NeuroNova in patients with newly diagnosed high-grade glioma.  Nov 2021 Press Release

INVO_oneline.png

Several Northwestern startups will be in San Francisco from Jan 9-11.


If you would like to meet any Northwestern startups (complete list here) in person or virtually OR hear about new Northwestern incubator programs, please contact us.

REQUEST A PARTNERING SESSION


HEALTHCARE TECHNOLOGIES

Acuitive logo.jpg

STARTUP: Acuitive Technologies

(Sublicensee of NU Startup VesselTek)

FACULTY FOUNDER: Guillermo Ameer


Accuitive has developed a bioresorbable biomaterial technology, known as Citregen™ with unique chemical and mechanical properties for musculoskeletal surgical applications. 



APPLICATION: MUSCULOSKELETAL SURGERY

NEWS: 

  • Stryker announced launch of CITRELOCK™ Tendon Fixation Device System. Sept 2021 Announcement
  • Received 3 510(k) clearances from FDA for the CITREFIX™ Knotless Suture Anchor System, CITRESPLINE™ and CITRELOCK™ Ligament Reconstruction Devices, and CITRELOCK™ Interference Screw System.  Press Releases
aivo-logo.png

STARTUP: Aivo

FACULTY FOUNDER: Vania Apkarian


Aivo has developed a remote assisted self-care solution for chronic pain patients using proprietary digital biomarkers and machine learning models to create dynamic individualized treatment plans.  individualized treatment plans. Instead of transient pain relief, the Aivo treatment targets the root cause of chronic pain and provides long term pain relief without the risks, costs or side effects of opioids or surgery.



APPLICATION: CHRONIC PAIN


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Aivo is planning to raise a Series A round ($10-20M) in 2022.

Amphix logo.png

STARTUP: Amphix Bio

FACULTY: Samuel Stupp


Amphix Bio's core technology, the peptide amphiphile nanofiber, uses natural building blocks to instruct cells to initiate regenerative processes. The modularity in the chemistry of the nanofibers enables a wide range of promising therapies for bone, cartilage, muscle, heart and neural regeneration in the brain and spinal cord.


APPLICATION: REGENERATIVE BIOMATERIALS

NEWS:

  • Completed $3.8M Fundraising round
  • Developed new product formulation for spinal fusion procedures to treat back pain
  • Initiated FDA discussion on regulatory pathway for spinal fusion product

 

\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \

 

**PARTNERING: Amphix is interested in discussions with potential future investors in the regenerative medicine space.

Dimension Inx_Horizontal Logo_Horizontal Logo_350.png

STARTUP: Dimension Inx

FACULTY FOUNDER: Ramille Shah


Dimension Inx develops 3D-printed therapeutic products, leveraging its next-gen biomaterials platform to create microenvironments that direct the body's cells to rebuild healthy tissues. The company recently submitted a 510K package for its first therapeutic implants for maxillofacial bone reconstruction. It continues to advance its internal pipeline in hard and soft tissue as well as reproductive health, while building revenue-generating strategic partnerships.



APPLICATION: BIOMATERIALS


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Dimension Inx is planning a Series A round in mid-2022 to advance their internal pipeline and expand commercial infrastructure, building on their $5.7M seed financing.


**PARTNERING: Dimension Inx is interested in join development partnerships for hard and soft tissue regenerative products.

Epicore small logo.png

STARTUP: Epicore Biosystems

FACULTY FOUNDER: John Rogers


Epicore produces skin-like wearable microfluidic solution that non-invasively measure sweat biomarkers, skin health, and physiology, in real-time. Epicore is collaborating with strategic partners such as Gatorade, Chevron and LEO Pharma.

APPLICATION: BIOELECTRONICS

NEWS: 



\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Epicore is in the final stages of completing its Series A investment round ($10M). They have 2 key strategics and several traditional VC investors for this oversubscribed round.



**PARTNERING: Epicore is actively pursuing key strategics in the pharmaceuticals and medical tech sectors to join its Series A.

Lung Healing Tech small logo.png

STARTUP: Lung Healing Technologies

FACULTY FOUNDER: Ankit Bharat


Lung Healing is developing monitors for sensing CO2, O2, and pressure in chest drains.



APPLICATION: CHEST DRAINAGE

NEWS: Completed the Health Wildcatters accelerator program.


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Lung Healing Technologies is raising $300k in seed funding.

MeshSuture 2.jpg

STARTUP: MSI

FACULTY: Gregory Dumanian


MSI has developed Duramesh™, the world's first suturable mesh. Duramesh combines the desirable principles of a mesh repair, with the placement precision of a suture. It distributes forces at the suture-tissue interface, while dramatically minimizing the amount of implanted foreign material and surgical complexity required for implantation. Duramesh is pending 510(k) clearance and is not yet available for sale in the USA.


APPLICATION: SURGERY

NEWS:

  • Received ISO 13485:2016 Certification of its Quality Management System
  • Received CE Mark Product Certification allowing market access to the European continent. Duramesh is now available for sale in the EU and UK.
  • Achieved first clinical use in the EU
M2Dx Logo.png

STARTUP: Minute Molecular Diagnostics

FACULTY FOUNDER: David Kelso


Minute Molecular Diagnostics has developed a quantitative PCR system that identifies infectious viral and bacterial agents in less than 15 minutes, operated by non-laboratory personnel with less than 1 minute hands on time. DASH's small foot print (11"Dx15"Hx4"W) supports hospital and outside hospital testing.


INDICATION: POC DIAGNOSTICS

NEWS: Awarded $21.3 M from NIH RADx Initiative to accelerate manufacturing of DASH 15 min PCR COVID-19 Test. April 2021 Press Release

_________* SF 2022 *_________

rhaeos-logo.png

STARTUP: Rhaeos

FACULTY FOUNDER: John Rogers


Rhaeos is developing FlowSense, a platform technology and noninvasive wireless, wearable skin patch that can monitor bodily fluid flow peripherally throughout the body. The company's first market will be neurosurgery for hospital and home applications.


APPLICATION: CHRONIC MEDICAL CONDITIONS, HYDROCEPHALUS

NEWS:

  • Received FDA Breakthrough Device Designation for their first device FlowSense™ scheduled for market launch in 2022. June 2021 Press Release
  • Received $4M NIH SBIR grant for outcomes based studies of FlowSense™ Sept 2021 Press Release
  • Closed an oversubscribed $2M seed round with value inflection points including FDA de novo 510(k) approval and market launch


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FINANCING: Rhaeos is closing their seed round this month and looks to connect with potential Series A medical device investors.


**PARTNERING: Rhaeos is interested in opportunities with strategic players in neurosurgery, hydrocephalus and patient monitoring devices.

_________* SF 2022 *_________

Sibel_Logo.png

STARTUP: Sibel Health

FACULTY FOUNDER: John Rogers


Sibel has developed the ANNE One—a flexible, wireless vital signs monitoring platform for clinical decision-making. Sibel delivers better patient health data through the development of their soft flexible sensors that are powered and operated by advanced software and analytics and cloud-optimized for AI and ML.



APPLICATION: PATIENT MONITORING

NEWS:

  • Announced 510(k) clearance from FDA for its ANNE One platform. Oct 2021 Press Release
  • Launched ANNE Discovery enabling powerful physiological data collection system for clinical trials with 6 Fortune 500 pharma companies.


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**FUNDRAISING: Sibel is currently raising a Series B round ($40-50M) with participation of Series A investors.



**PARTNERING: Sibel is also interested in joint development opportunities.

_________* SF 2022 *_________

Surgical Innovation Associates.png

STARTUP: SIA Health

FACULTY FOUNDER: John Kim


SIA has developed DuraSorb®, a fully resorbable synthetic mesh for soft tissue support in reconstructive and cosmetic surgery.



APPLICATION: SURGERY

NEWS:

  • DuraSorb is FDA cleared, CE Marked, and commercially available.
  • Recently closed oversubscribed $15M Series B to expand direct sales team, with presently over 140 accounts and more than 40 hospitals ordering.


\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \



**PARTNERING: SIA welcomes discussions with key medtech strategics in soft tissue support, general surgery, plastic and reconstructive surgery, and biomaterials.

SwiftScale.png

STARTUP: SwiftScale Biologics

FACULTY FOUNDER: Michael Jewett


SwiftScale Biologics develops cell-free protein synthesis (CFPS) technology, eliminating the constraints of working with living cells in the drug manufacturing process. CFPS leads to faster production times, less variability across batches, and greater scalability with more challenging proteins.


APPLICATION: PROTEIN MANUFACTURING

NEWS: Acquired by National Resilience. Dec 2021 Press Release

REQUEST A PARTNERING SESSION

RECENT RESEARCH HIGHLIGHTS

stupp mice hind legs.png

THERAPEUTIC FOR SPINAL CORD INJURY

FACULTY: Samuel Stupp

AREA OF RESEARCH: Developed new injectable therapy that harnesses synthesized supramolecular peptide fibril scaffolds in promoting nerve regeneration. Administration of a single injection to tissues surrounding the spinal cords of paralyzed mice appears to reverse paralysis and repairs tissues after severe spinal cord injury.

SCIENCE PAPER | NORTHWESTERN COVERAGE

Rogers dissolvable pacemaker.png

TRANSIENT BIOCOMPATIBLE PACEMAKER

FACULTY: John Rogers

AREA OF RESEARCH: Developed first-ever transient pacemaker — a wireless, battery-free, fully implantable pacing device that could be used in patients who need temporary pacing after cardiac surgery or while waiting for a permanent pacemaker. All components of the pacemaker are biocompatible and naturally absorb into the body’s biofluids over the course of five to seven weeks, without needing surgical extraction. NATURE BIOTECH PAPER | NORTHWESTERN COVERAGE

Surmeier Nature Fig 1i.png

ADVANCES IN MODELING PARKINSON'S DISEASE

FACULTY: D. James Surmeier

AREA OF RESEARCH: Identified causal relationship between damage to mitochondria in dopamine neurons and human-like parkinsonism. Using a new disease model in mice, the team replicated the slow progression of the disease in humans. These findings may help identify people who have a high probability of developing Parkinson's within five to 10 years.

NATURE PAPER | NORTHWESTERN COVERAGE

For additional stories at McCormick School of Engineering, visit here.

For additional stories at Feinberg School of Medicine, visit here.